Evidence that Parkinson’s drug levodopa may cause freezing of gait should be addressed with new studies that investigate a possible shift to alternative dosing strategies or treatment options. That’s ...

As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal Pharmaceuticals has taken home the gold in the U.S. Late Wednesday, the FDA ...

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by researchers. It promises easier treatment, fewer missed doses, and better ...

Former college football coach Mark Richt announced Tuesday that he is taking levodopa to treat Parkinson’s disease. The former head coach of the University of Georgia and the University of Miami asked ...

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time ...

Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.

HAYWARD, Calif., April 11, 2014 -- Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY ...